Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

GILD - Gilead Sciences Inc

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by bigbear0083, Mar 31, 2016.

  1. bigbear0083

    bigbear0083 Content Manager
    Staff Member

    Joined:
    Mar 29, 2016
    Messages:
    22,799
    Likes Received:
    8,264
    [​IMG]

    [​IMG]

    [​IMG]

    Gilead Sciences (GILD) is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired two companies which were developing drugs to treat patients with pulmonary diseases.

    The company's current commercially available products include Atripla, Complera, Emtriva, Viread, Tybost, Vitekta, Truvada, Stribild, Harvoni, Hepsera, Sovaldi, Zydelig,Letairis, Lexiscan, Ranexa, Cayston, Tamiflu, AmBisome, and Macugen.

    Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2015, the company had approximately 7,900 full-time employees. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

    The company's name and logo refer to the Balm of Gilead, inspired by a 1965 play by Lanford Wilson featuring the underworld adventures of the patrons of the namesake cafe.
     
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    7,293
    Likes Received:
    2,268
    Reported after close today (4/28/16)
    Earnings: EPS $3.03 Revenue $7.8B
    Estimates: EPS $3.13 Revenue $8.08B

    Down 6.07% in after hours so far
     
  3. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    GILD revenues from its Hep C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations. Down AH -7% !
     
  4. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    If you are are pushing GILD to make a highly accretive acq, it will not be cheap even at these prices. Be really careful what you wish for.
     
  5. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    7,293
    Likes Received:
    2,268
    Reported after close today (7/25/16)
    Earnings: EPS $3.08 Revenue $7.78B
    Estimates: EPS $3.02 Revenue $7.79B

    Down 3.90% after hours
     
  6. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    Bears, you will win today but if it's EOD price @ $85 or higher, we could see $92 @ the EOW thanks 2 Fed Reserve not raising rates.
     
  7. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    7,074
    Likes Received:
    2,094
    Oh oh, new lows incoming!
     
  8. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    7,293
    Likes Received:
    2,268
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Stifel
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Buy
    Previous Price Target: N/A
    Current Price Target: $100
     
  9. Markus Teller

    Markus Teller New Member

    Joined:
    Oct 22, 2016
    Messages:
    4
    Likes Received:
    1
    Not many investors would argue that Gilead Sciences, Inc. (NASDAQ:GILD) has been beaten down over the last two years. After all, in 2015 the stock traded as high as $123.00, but now trades at $72.00. Most investors are fearful of bottom fishing but I have made millions off of it. The key is being patient and letting the stock chart tell YOU when to buy. Too many investors force their personal views on a stock and the stock just takes all their money. In the case of Gilead Sciences, the stock may be starting to alert us to a buying opportunity. Notice on the stock chart how Gilead had a big pop starting in early November, the first big one in a long time and has since slowly settled back down, falling towards the lows. The key for me to buy is seeing if the previous low can hold. In other words, I do not want to see this slow grind lower take out the $71 level,making a higher low. If it can hold and the stock starts to inch up, I am a strong buyer. Pay attention, these types of trades can make you a lot of money.





    [​IMG]
     
    StockJock-e likes this.
  10. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    704
    Likes Received:
    62
    StockJock-e likes this.
  11. AnthonyJackson

    AnthonyJackson New Member

    Joined:
    Oct 28, 2016
    Messages:
    16
    Likes Received:
    10
    Biotechnology stocks have been weak the last few days, and let's be honest, all of 2016. An attack by Donald Trump on drug prices did the trick over the last few days, punishing a majority of biotechnology and pharma plays. One stock that did not fall? Gilead Sciences, Inc. (NASDAQ:GILD). Last Thursday, Gilead did hit a new 52 week low. However, during that session it also reversed back to the upside. The reversal off a new 52 week low caused a bullish bottoming tail formation. This is a buy signal by itself but now Gilead Sciences has followed it up with something even better. Friday and Monday saw upside even when the Biotech Index was down. This confirms the bottom and signals major upside to smart investors. This is a strong buy with an upside target of $88.00.




    [​IMG]
     
  12. LloydWCoutee

    LloydWCoutee Active Member

    Joined:
    May 4, 2016
    Messages:
    724
    Likes Received:
    58
    Love the new ad campaign, we'll all be taking Harvoni by the end of 2017. LOL
     
  13. heyimsnuffles

    heyimsnuffles Active Member

    Joined:
    Nov 22, 2016
    Messages:
    467
    Likes Received:
    83
    Trying to bottom, still looks gross IMO
     
  14. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    7,074
    Likes Received:
    2,094
    Is that a technical term? :p
     
  15. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    704
    Likes Received:
    62
  16. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    704
    Likes Received:
    62
    Many investors and analysts alike have been trying to pick a bottom in the stock this year, but the stock stubbornly continues to trade below $75 a share. Worrying downward trends with respect to the company's HCV division remain the dominant theme among investors.
     
  17. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    704
    Likes Received:
    62
  18. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    704
    Likes Received:
    62
    $GILD hammered on poor guidance. Headed to $63.50
     
  19. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    7,074
    Likes Received:
    2,094
    Getting cheaper, but lost that $70 support which it has held for so long.
     
  20. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    This week we find out if we are going to the 50s or 80s all eyes on HIV. Needs to take the lead or it's done for a while.
     

Share This Page